
Alpine Immune Sciences Revenue | ALPN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Alpine Immune Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.9 M | 30.1 M | 23.4 M | 9.34 M | 1.74 M | 705 K | 1.73 M | 2.95 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.9 M | 705 K | 16.1 M |
Quarterly Revenue Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.03 M | - | 10 M | 8.59 M | 9.39 M | - | 8.37 M | 5.29 M | 13.6 M | - | 8.52 M | 7.19 M | 3.2 M | - | 1.91 M | 688 K | 1.09 M | - | 289 K | 567 K | - | - | - | 390 K | 315 K | - | 128 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.6 M | 128 K | 4.81 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MacroGenics
MGNX
|
150 M | $ 1.97 | -0.76 % | $ 124 M | ||
|
Protagonist Therapeutics
PTGX
|
46 M | $ 121.72 | -2.2 % | $ 7.74 B | ||
|
Novo Nordisk A/S
NVO
|
309 B | $ 37.8 | -2.82 % | $ 168 B | ||
|
Marker Therapeutics
MRKR
|
3.55 M | $ 1.1 | -17.05 % | $ 16.8 M | ||
|
Arcus Biosciences
RCUS
|
247 M | $ 15.62 | -1.01 % | $ 1.68 B | ||
|
NextCure
NXTC
|
22.4 M | $ 6.62 | -2.43 % | $ 35.2 M | ||
|
United Therapeutics Corporation
UTHR
|
3.18 B | $ 553.08 | -1.08 % | $ 24.5 B | ||
|
Kymera Therapeutics
KYMR
|
39.2 M | $ 115.19 | -3.52 % | $ 9.73 B | ||
|
Oragenics
OGEN
|
37.7 K | $ 0.16 | -6.16 % | $ 345 K | ||
|
Ovid Therapeutics
OVID
|
7.25 M | $ 2.2 | -5.98 % | $ 286 M | ||
|
Relay Therapeutics
RLAY
|
15.4 M | $ 16.11 | 1.26 % | $ 2.76 B | ||
|
Precigen
PGEN
|
9.68 M | $ 4.21 | 1.08 % | $ 1.32 B | ||
|
Avidity Biosciences
RNA
|
18.8 M | $ 6.94 | -0.57 % | $ 956 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
4.36 K | $ 0.66 | -7.55 % | $ 3.95 M | ||
|
Praxis Precision Medicines
PRAX
|
8.55 M | $ 300.01 | -3.5 % | $ 6.75 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
12.1 M | $ 3.22 | -1.08 % | $ 248 M | ||
|
Ocular Therapeutix
OCUL
|
52 M | $ 5.57 | -5.03 % | $ 1.04 B | ||
|
Outlook Therapeutics
OTLK
|
1.41 M | $ 0.39 | -2.79 % | $ 13.6 M | ||
|
uniQure N.V.
QURE
|
16.1 M | $ 19.32 | -4.5 % | $ 1.11 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
673 M | $ 16.46 | -4.41 % | $ 1.62 B | ||
|
Rafael Holdings
RFL
|
874 K | $ 0.94 | 5.89 % | $ 48.3 M | ||
|
REGENXBIO
RGNX
|
170 M | $ 7.16 | -0.35 % | $ 369 M | ||
|
Rigel Pharmaceuticals
RIGL
|
294 M | $ 40.05 | -2.78 % | $ 720 M | ||
|
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
27.6 M | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
49.3 K | $ 1.27 | -8.27 % | $ 49.8 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
12 B | $ 514.68 | -1.15 % | $ 132 B | ||
|
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B | ||
|
SELLAS Life Sciences Group
SLS
|
1 M | $ 13.67 | -8.01 % | $ 1.49 B | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Abcam plc
ABCM
|
362 M | - | - | $ 4.9 B | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-82 K | $ 0.63 | -7.05 % | $ 67.2 M | ||
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Affimed N.V.
AFMD
|
8.28 M | - | -34.95 % | $ 21.5 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
12 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |